{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:37:40Z","timestamp":1791607060817,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s11938-019-00224-7","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T04:41:50Z","timestamp":1549600910000},"page":"161-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Overlap Between GERD and Functional Esophageal Disorders\u2014a Pivotal Mechanism for Treatment Failure"],"prefix":"10.1007","volume":"17","author":[{"given":"Ofer Z.","family":"Fass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Fass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"issue":"8","key":"224_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900\u201320.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"224_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/gut.2004.051821","volume":"54","author":"J Dent","year":"2005","unstructured":"Dent J, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710\u20137.","journal-title":"Gut"},{"issue":"6","key":"224_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871\u201380.","journal-title":"Gut"},{"issue":"3","key":"224_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308\u201328; quiz 329.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"224_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","volume":"32","author":"H El-Serag","year":"2010","unstructured":"El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720\u201337.","journal-title":"Aliment Pharmacol Ther"},{"issue":"s3","key":"224_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1440-1746.2012.07064.x","volume":"27","author":"R Fass","year":"2012","unstructured":"Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27(s3):3\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"224_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","volume":"22","author":"R Fass","year":"2005","unstructured":"Fass R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005;22(2):79\u201394.","journal-title":"Aliment Pharmacol Ther"},{"key":"224_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1572-0241.2008.01791.x","volume":"103","author":"R Tutuian","year":"2008","unstructured":"Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol. 2008;103:1090\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"224_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/gut.2005.087668","volume":"55","author":"I Mainie","year":"2006","unstructured":"Mainie I, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55(10):1398\u2013402.","journal-title":"Gut"},{"issue":"9","key":"224_CR10","first-page":"1","volume":"30","author":"L Hillman","year":"2017","unstructured":"Hillman L, et al. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30(9):1\u201315.","journal-title":"Dis Esophagus"},{"issue":"2","key":"224_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1046\/j.1365-2036.2003.01394.x","volume":"17","author":"MF Vela","year":"2003","unstructured":"Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17(2):243\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"224_CR12","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/bjs.5493","volume":"93","author":"I Mainie","year":"2006","unstructured":"Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intraluminal impedance\u2013pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. BJS. 2006;93(12):1483\u20137.","journal-title":"BJS"},{"key":"224_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1572-0241.2005.41210.x","volume":"100","author":"S Charbel","year":"2005","unstructured":"Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005;100:283\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"224_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/bjs.4614","volume":"91","author":"AD Jenkinson","year":"2004","unstructured":"Jenkinson AD, Kadirkamanathan SS, Scott SM, Yazaki E, Evans DF. Relationship between symptom response and oesophageal acid exposure after medical and surgical treatment for gastro-oesophageal reflux disease. BJS. 2004;91(11):1460\u20135.","journal-title":"BJS"},{"issue":"9","key":"224_CR15","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/nmo.12644","volume":"27","author":"PJ Kahrilas","year":"2015","unstructured":"Kahrilas PJ, Keefer L, Pandolfino JE. Patients with refractory reflux symptoms: what do they have and how should they be managed? Neurogastroenterol Motil. 2015;27(9):1195\u2013201.","journal-title":"Neurogastroenterol Motil"},{"key":"224_CR16","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/ajg.2009.240","volume":"104","author":"A Gasiorowska","year":"2009","unstructured":"Gasiorowska A, Navarro-Rodriguez T, Wendel C, Krupinski E, Perry ZH, Koenig K, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol. 2009;104:2005\u201313.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"224_CR17","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.cgh.2013.10.026","volume":"12","author":"WO Rohof","year":"2014","unstructured":"Rohof WO, Bennink RJ, de Jonge H, Boeckxstaens GE. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2014;12(10):1647\u201355.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"224_CR18","doi-asserted-by":"publisher","unstructured":"Abdallah, J., et al. Most patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy also have functional esophageal disorders. Clin Gastroenterol Hepatol. 2018. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2018.06.018","DOI":"10.1016\/j.cgh.2018.06.018"},{"issue":"6","key":"224_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2016.02.012","volume":"150","author":"Q Aziz","year":"2016","unstructured":"Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Esophageal disorders. Gastroenterology. 2016;150(6):1368\u201379.","journal-title":"Gastroenterology"},{"issue":"4","key":"224_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.5056\/jnm17097","volume":"23","author":"T Yamasaki","year":"2017","unstructured":"Yamasaki T, Fass R. Reflux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil. 2017;23(4):495\u2013503.","journal-title":"J Neurogastroenterol Motil"},{"issue":"2","key":"224_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.gastro.2017.07.049","volume":"154","author":"CP Gyawali","year":"2018","unstructured":"Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302\u201318.","journal-title":"Gastroenterology"},{"issue":"11","key":"224_CR22","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1111\/nmo.12666","volume":"27","author":"S Roman","year":"2015","unstructured":"Roman S, Keefer L, Imam H, Korrapati P, Mogni B, Eident K, et al. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux. Neurogastroenterol Motil. 2015;27(11):1667\u201374.","journal-title":"Neurogastroenterol Motil"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-019-00224-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-019-00224-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-019-00224-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:27:41Z","timestamp":1581121661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-019-00224-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1007\/s11938-019-00224-7","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"assertion":[{"value":"8 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ofer Fass declares that he has no conflict of interest. Ronnie Fass declares that he is an advisor for Ironwood, Mecleri Therapeutics, Takeda and Chinoin, speaker for Ostrazeneca, Takeda, Cadilla and Diversitek and receive research money from Ironwood.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights and informed consent"}}]}}